目的:我们使用来自波哥大强制性信息系统的数据,进行了一项研究,以评估针对COVID-19的同源疫苗接种时间表的疫苗有效性(VE)。哥伦比亚。
方法:一项来自波哥大(哥伦比亚)成年人的测试阴性病例对照研究,2021年3月1日至2022年2月25日。我们评估了Mul期间有症状的COVID-19病例中的VE,Delta,和Omicron在波哥大的统治时期,与性别相匹配的控制,年龄(±5岁),和测试日期(±7天),使用情况:控制比为1:1。我们选择了ChAdOx1,CoronaVac,BNT162b2、mRNA-1273和Ad26。COV2.S.在调整后的条件逻辑回归中,VE被报告为1减去赔率比,他们的95%置信区间(CI)。P值<0.05被认为是统计学上显著的。
结果:52,913例与对照组相匹配,Mu的16,722,达美航空14,094,和Omicron的22,097。在使用单价BNT162b2(VE:69;95%CI,65至72)疫苗和ChAdOx1(VE:64;95%CI,31至81)进行全面疫苗接种的Mu周内,对COVID-19的VE较高,而CoronaVac(P<0.001)和Ad26显著较低。COV2.S(P=0.005)。在三角洲期间,BNT162b2对COVID-19的VE较高(VE:55;95%CI,51至58)。Omicron期间COVID-19病例的VE较高,加强剂量为单价BNT162b2(VE:45;95%CI,34至54)。主要系列和升压器的VE为ChAdOx1,Ad26。COV2.S,CoronaVac没有显示对Omicron的保护。
结论:我们的研究为OmicronmRNA疫苗的保护作用提供了进一步的证据,并保证针对症状性感染的保护持续时间可能仅持续几个月。
We carried out a
study to estimate the vaccine effectiveness (VE) of homologous vaccination schedules against COVID-19, using data from mandatory information systems from Bogota, Colombia.
A test-negative case-control
study in adults from Bogota (Colombia), between March 1st of 2021 and February 25th of 2022. We assess VE among symptomatic COVID-19 cases during the Mul, Delta, and Omicron predominance periods in Bogota, with controls matched by sex, age (±5 years), and date of testing (±7 days), using a case:control ratio of 1:1. We selected homologous vaccination schedules with ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S. VE was reported as one minus the odds ratio in adjusted conditional logistic regressions, with their 95% confidence intervals (CI). A p-value < 0.05 was considered statistically significant.
52,913 cases were matched to controls, 16,722 for Mu, 14,094 for Delta, and 22,097 for Omicron. VE was high against COVID-19 during Mu weeks with full vaccination using the monovalent BNT162b2 (VE: 69; 95% CI, 65 to 72) vaccine and ChAdOx1 (VE: 64; 95% CI, 31 to 81) and significantly lower with CoronaVac (P < 0.001) and Ad26.COV2.S (P = 0.005). During Delta, VE against COVID-19 was higher with BNT162b2 (VE: 55; 95% CI, 51 to 58). The VE for COVID-19 cases during Omicron was higher with a booster dose of monovalent BNT162b2 (VE: 45; 95% CI, 34 to 54). The VE of primary series and booster for ChAdOx1, Ad26.COV2.S, and CoronaVac did not show protection for Omicron.
Our
study provides further evidence on the protective effect of mRNA vaccines for Omicron, and warrant that the duration of protection against symptomatic infection may last for only a few months.